Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

In a video shared to TikTok via her page, @lucy52915, which has racked up more than 750,000 views, she revealed pictures of ...

A WOMAN who’s shed nearly 25% of her bodyweight thanks to Mounjaro has revealed which foods she steered clear of. TikToker ...

Fitness experts say using weight-loss drugs is just one piece of the puzzle for many attempting to live healthier ...

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.

Pre-diabetes now affects as many as one-third of children ages 12-17. As a physician this is why Ozempic should still not be ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

It turns out that obesity may be much more complicated than we thought, with the condition potentially existing in up to 11 ...

From legal pitfalls to temperature-sensitive drugs, here’s how to travel safely and legally with your medication ...